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introduction: Herpes zoster, which can have a major impact on quality of life, results 
from reactivation of a latent varicella zoster virus (VZV) infection. We hypothesized that 
giant cell arteritis (GCA) patients are at increased risk of herpes zoster because of treat-
ment with high-dose glucocorticoids and advanced age. Aim of the study, therefore, was 
to determine cell-mediated and humoral immunity to VZV in patients with GCA, patients 
with closely related disease polymyalgia rheumatica (PMR; treated with lower doses of 
glucocorticoids) and healthy controls (HCs).
Methods: Cell-mediated immunity to VZV was determined by performing interferon-γ 
(IFNγ) enzyme-linked immunospot and intracellular cytokine flow cytometry measure-
ments in 11 GCA and 15 PMR patients and in 26 age/sex-matched HCs. Immunoglobulin 
G antibodies to VZV glycoprotein (VZV-IgG) were measured in serum samples of 35 GCA 
and 26 PMR patients at different times of follow-up and in 58 age and sex-matched HCs 
by an enzyme-linked immunosorbent assay.
results: The number of VZV-specific IFNγ spot-forming cells was significantly lower in 
GCA patients on treatment, than in age-matched HCs (p = 0.029), but was not different 
in PMR patients on treatment. Similar levels of VZV-IgG were found in GCA and PMR 
patients at baseline, compared to HCs.
conclusion: The finding of a decreased cell-mediated immunity to VZV, known to 
be of great importance in defense to the virus, indicates an increased herpes zoster 
risk in GCA patients compared to an already at-risk elderly population. Herpes zoster 
vaccination is, therefore, of special importance in GCA patients, and would ideally be 
administered at time of diagnosis. Interestingly, as VZV was suggested to be the trigger 
in GCA pathogenesis, similar levels of VZV-IgG were found in GCA patients at time 
of diagnosis and age-matched HCs, indicating that GCA patients did not experience 
herpes zoster substantially more often in the months preceding diagnosis than controls.
Keywords: giant cell arteritis, polymyalgia rheumatica, varicella zoster virus, herpes zoster, cell-mediated 
immunity, humoral immunity, viral immunity, glucocorticoids
Abbreviations: GCA, giant cell arteritis; PBMC, peripheral blood mononuclear cell; PMR, polymyalgia rheumatica; SEB, 
staphylococcal enterotoxin B; VZV, varicella zoster virus.
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inTrODUcTiOn
Herpes zoster is caused by reactivation of a latent varicella zoster 
virus (VZV) infection (1). Almost the whole adult population of 
temperate countries has experienced a primary VZV infection in 
childhood (known as varicella or chickenpox) and is, therefore, 
at risk of herpes zoster (2). Postherpetic neuralgia (pain lasting 
>90 days after onset of rash) is the most common complication 
of herpes zoster occuring in 8–27% of patients (3–6). Impact on 
quality of life of herpes zoster and postherpetic neuralgia can be 
major (3, 4).
With advancing age, a rise in the incidence of herpes zoster 
occurs concomitantly with a decline in VZV-specific cell-medi-
ated immunity. The estimated incidence of HZ is about 3.4–4.82 
per 1,000 person years in the general population which increases 
to more than 11 per 1,000 person years in those above 80 years 
of age (7).
Giant cell arteritis (GCA) and the closely related polymyalgia 
rheumatica (PMR) are inflammatory rheumatic disorders that 
occur almost exclusively in older adults (8). In our hospital, GCA 
patients usually start on 40–60 mg of prednisolone daily, while 
PMR patients start at a lower dose of 15–20  mg prednisolone 
daily. In both patient groups, the prednisolone dose is slowly 
tapered. Use of glucocorticoids is associated with a higher herpes 
zoster risk (9–14). Both because of advanced age and high-dose 
glucocorticoid use, especially GCA patients could be expected to 
have an increased herpes zoster risk.
A live attenuated herpes zoster vaccine was licensed in the 
US in 2006 for use in immunocompetent persons above 60 years 
of age (15). In this group, it was shown to be safe and effective 
in preventing herpes zoster and postherpetic neuralgia (6). The 
Advisory Committee on Immunization Practices (ACIP) recom-
mends the zoster vaccine for all persons aged ≥60 years (16). Like 
immunocompetent older persons, GCA and PMR patients may 
benefit from zoster vaccination.
The ACIP in 2008, however, also stated that the vaccine should 
not be administered to persons on immunosuppressive therapy, 
including high-dose glucocorticoids (≥20 mg/day of prednisone 
or equivalent) lasting two or more weeks, although this recom-
mendation was based on expert opinion only (16). The 2010 
European League Against Rheumatism (EULAR) recommen-
dations for vaccination in patients with rheumatic diseases are 
inconclusive, stating that zoster vaccination may be considered 
in patients with rheumatic diseases (17).
Since the time of ACIP and EULAR recommendations, a large 
retrospective cohort study in patients with immune-mediated 
diseases, including patients using oral glucocorticoids and even 
biologicals, has shown that zoster vaccination is associated with 
a reduced incidence of herpes zoster, also within 42 days of vac-
cination (a safety concern, as the vaccine is live attenuated) (10). 
A randomized controlled trial in patients using glucocorticoids 
(with a limited number of included patients using more than 
10 mg daily equivalent of prednisone), comparing live attenuated 
zoster vaccine to placebo vaccine, demonstrated that zoster vac-
cination was well tolerated (18).
When balancing pros and cons of zoster vaccination in GCA 
patients, information on the pre-existing cellular and humoral 
immunity to VZV is essential. The aim of this study, therefore, 
was to determine both cell-mediated immunity (most important 
in the defense to the virus) and humoral immunity to VZV in 
patients with GCA, the closely related PMR and age/sex-matched 
healthy controls (HCs).
MaTerials anD MeThODs
study Population and Procedures
Prospectively collected serum samples and peripheral blood 
mononuclear cells (PBMCs) from patients with GCA and PMR, 
and matched HCs were used. Study procedures have been 
described previously (19, 20).
Giant cell arteritis patients either had a positive temporal 
artery biopsy and/or positive 18F-fluorodeoxyglucose-positron 
emission tomography-computed tomography (FDG PET-CT). 
PMR patients fulfilled the Chuang/Hunder criteria or had a FDG 
PET-CT positive scan for PMR (21).
Serum was stored at −20°C, and PBMCs were stored in liquid 
nitrogen until use. After evaluating cell viability by trypan blue 
staining, PBMCs were used in enzyme-linked immunospot 
(ELISpot) assays and flow cytometry analyses.
Samples for humoral analyses were randomly selected, and 
samples from patients at different times of follow-up were used: 
T = 0, T ≤ 2 months, T = approximately 6 months, T = approxi-
mately 1 year, and T = approximately 2 years, or more. At T = 0, 
patients had not yet received treatment with prednisolone (or 
other immunosuppressive drugs). At T ≤ 2 months, patients were 
within 2 months of follow-up and had all started prednisolone 
treatment.
Medical records from both patients and HCs were checked for 
a history of herpes zoster within 2 years before disease onset or 
sample collection. In The Netherlands, zoster vaccination is not 
advised and costs are not compensated in the national health-care 
system. Since all patients were Dutch, it could safely be presumed 
that none of the study subjects had been vaccinated against herpes 
zoster.
The study was approved by the institutional review board 
of the University Medical Centre Groningen (METc2012/375 
for HCs and METc2010/222 for GCA and PMR patients), 
and written informed consent was obtained from all study 
participants.
interferon-γ (iFnγ) elispot assay
Interferon-γ (IFNγ) ELISpot assay was performed as described 
previously (22). PBMCs were stimulated for 48 h with ultraviolet 
(UV)-inactivated varicella vaccine (Provarivax; Sanofi Pasteur). 
PBMCs stimulated with concanavalin A were used as controls. A 
negative control consisted of PBMCs in culture medium alone. 
After staining, spots were counted using an automated reader 
(AID EliSpot Reader; Autoimmun Diagnostika GmbH). The 
mean number of spots in the negative control sample was sub-
tracted from the mean number of spots in the VZV-stimulated 
wells. Results are referred to as the number of IFNγ spot-forming 
cells per 2 × 105 PBMCs.
TaBle 1 | Characteristics of patients and healthy controls (HCs).
hcs (n = 26) gca patients (n = 11) PMr patients (n = 15)
Sex, no. female/male 19/7 8/3 10/5
Age at sample date, median (interquartile range) years 73.2 (63.2–76.9) 73.2 (67.0–74.8) 71.3 (63.3–78.2)
GCA diagnosis: FDG PET-CT|TAB|FDG PET-CT + TAB NR 6|3|2 NR
PMR diagnosis: FDG PET-CT|Chuang|FDG PET-CT + Chuang NR 0|0|2 1|4|10
Time since diagnosis, median (interquartile range) months NR 8.1 (4.9–9.1) 9.1 (8.0–10.0)
Cumulative prednisolone dosage, median (interquartile range) mg NR 5,843 (5,028–8,239) 3,385 (2,413–5,320)
Use of immunosuppressants other than prednisolone, no. (%) NR 2 (18)a 2 (13)b
No. of patients that experienced relapse since diagnosis (%) NR 1 (9) 4 (27)
Leukocyte count, median (interquartile range) 109 cells/L 5.50 (5.00–6.53) 9.80 (9.45–12.38)*** 8.30 (7.30–10.90)***
Lymphocyte count, median (interquartile range) 109 cells/L 1.75 (1.50–1.92) 1.68 (1.43–2.55) 1.37 (1.08–1.61)***
CD3+ lymphocyte count, median (interquartile range) 109 cells/L 1.24 (1.08–1.36) 1.30 (1.06–1.85) 1.06 (0.81–1.14)*
Hemoglobin, median (interquartile range) mmol/L 8.7 (8.2–9.2) 7.9 (6.6–8.3)** 8.3 (7.5–9.3)
ESR, median (interquartile range) mm/h 9 (4–19) 24 (14–42)* 13 (8–38)
CRP, median (interquartile range) mg/L <5 (<5–<5) 6 (<5–24)** 6.4 (<5–13)***
GCA, giant cell arteritis; PMR, polymyalgia rheumatica; FDG-PET/CT, no. of patients with 18F-fluorodeoxyglucose-positron emission tomography-computed tomography supporting 
diagnosis; TAB, no. of patients with temporal artery biopsy positive for GCA; NR, not reported; Chuang, no. of patients fulfilling the Chuang and Hunder PMR criteria; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein.
aTwo patients received methotrexate (both 15 mg/week).
bOne patient received methotrexate (15 mg/week) and one patient received leflunomide (10 mg/day).
*p-Value < 0.05; **p-value < 0.01; ***p-value < 0.001 for comparison to HC group.
3
Rondaan et al. Immunity to VZV in GCA and PMR
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1377
intracellular cytokine staining Flow 
cytometry
Fluorescent T cell barcoding staining for tumor necrosis factor 
alpha (TNFα), interleukin-2 (IL-2), and IFNγ was performed 
as described previously (23) after stimulating PBMCs using 
UV-inactivated varicella vaccine. PBMCs stimulated with 
staphylococcal enterotoxin B (SEB; Sigma-Aldrich) were used 
as positive controls. A negative control consisted of PBMCs 
in medium alone. PBMCs were stimulated for 18 h, of which 
the last 16 h in the presence of 10 µg/ml brefeldin A (Sigma-
Aldrich). Kaluza software (Beckman Coulter) was used for 
analyses. Percentages of antigen-specific cells were expressed as 
the percentage of CD69+ cytokine-producing CD4+ or CD8+ 
T cells.
antibody response to VZV
For quantitative detection of VZV-IgG antibodies, an in-house 
glycoprotein enzyme-linked immunosorbent assay was previ-
ously developed and validated (22). VZV purified glycoproteins 
(EastCoastBio) were used as antigen, and pooled human 
serum with known levels of anti-glycoprotein VZV was used 
as standard.
statistical analysis
Data were analyzed using SPSS 23 (IBM) and graphs were 
made using GraphPad Prism 5.0 (GraphPad Software). For 
correlations Spearman’s rho was used. To compare differences 
between either the GCA or the PMR group to the HC group, 
Mann–Whitney U and Fisher’s exact test were used as appro-
priate. Humoral immunity results at baseline were compared 
to the HC group separately for GCA and PMR patients using 
Mann–Whitney U tests. p-Values less than 0.05 (2-tailed) were 
considered significant.
resUlTs
characteristics of Patients and hcs
Characteristics of patients and controls are summarized in 
Table 1. Levels of VZV-IgG antibodies were measured in a larger 
number of samples, on different time points of follow-up. Patient 
and control characteristics are, therefore, separately summarized 
in Table S1 in Supplementary Material. All patients started with 
prednisolone and some relapsing patients used methotrexate or 
leflunomide as glucocorticoid sparing drug. No other immuno-
suppressive medication was used.
cellular immunity to VZV: iFnγ elispot 
assay
The number of IFNγ spot-forming cells was significantly 
lower among GCA patients on treatment as compared to HCs 
(p  =  0.029). PMR patients on treatment and HCs showed 
similar numbers of spot-forming cells. The median number of 
IFNγ spot-forming cells per 2 × 105 PBMCs in response to VZV 
stimulation was 47.5 (range 0–255) among HCs, 7 (range 0–69) 
among GCA patients, and 83 (range 0–279) in PMR patients 
(Figure 1).
cellular immunity to VZV: Flow cytometric 
analysis of cytokine Production
Upon stimulation with VZV, patients with GCA and HCs 
showed similar frequencies of cytokine-producing CD4+ T cells. 
Interestingly, higher frequencies of CD4+ T cells producing IFNγ 
and IL-2 were found in PMR patients compared to HC subjects 
(p = 0.019 and p = 0.048, respectively) (Figures 2A–C). Similar 
frequencies of cytokine-producing CD8+ T cells were observed 
in patient groups and controls following stimulation with VZV 
(Figures 3A–C).
FigUre 2 | Frequencies of cytokine-producing CD4+ T cells upon stimulation with varicella zoster virus (VZV) (a–c) and staphylococcal enterotoxin B (SEB, 
positive control) (D–F) in healthy control (HC) subjects (n = 23), giant cell arteritis (GCA) patients (n = 11) and polymyalgia rheumatica (PMR) patients (n = 15). 
Results are corrected for responses in non-stimulated cultures. Bars show the median. IFNγ, interferon-γ; TNFα, tumor necrosis factor α; IL-2, interleukin-2.
FigUre 1 | Levels of interferon-γ (IFNγ) spot-forming cells in response to 
varicella zoster virus stimulation. Numbers of IFNγ spot-forming cells per 
2 × 105 peripheral blood mononuclear cells in 24 healthy controls (HC) 
subjects, 9 giant cell arteritis (GCA) patients, 15 polymyalgia rheumatica 
(PMR) patients are shown. Results are corrected for responses in  
non-stimulated cultures from the same sample. Bars show the median.
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Upon SEB stimulation as positive control for stimulation, 
patients with GCA, PMR, and control subjects showed similar 
frequencies of IFNγ-, TNFα, and IL-2-producing CD4+ T cells 
(Figures  2D–F). For CD8+ T  cell cytokine production upon 
stimulation with SEB there was a trend toward a lower frequency 
of CD8+ T cells producing TNFα in GCA patients compared to 
HCs (p = 0.077) (Figures 3D–F).
humoral immunity to VZV
Median VZV-specific antibody levels of patients at baseline, before 
starting treatment, were similar in patient groups compared 
to HCs (p = 0.931 for GCA and p = 0.777 for PMR, Figure 4). 
Course of VZV–IgG antibody levels in GCA and PMR patients 
are shown in Figure 4.
reactivations of VZV
In the group of patients and controls in which VZV-specific IgG 
levels were determined (Figure 4), one patient was noted to have 
experienced herpes zoster about 3 months before GCA diagnosis. 
As can be expected, this patient showed a high VZV-IgG antibody 
level at time of diagnosis (7,100 IU/ml). In another patient, a very 
FigUre 3 | Frequencies of cytokine-producing CD8+ T cells upon stimulation with varicella zoster virus (VZV) (a–c) and staphylococcal enterotoxin B (SEB, 
positive control) (D–F) in healthy control (HC) subjects (n = 23), giant cell arteritis (GCA) patients (n = 11) and polymyalgia rheumatica (PMR) patients (n = 15). 
Results are corrected for responses in non-stimulated cultures. Bars show the median. IFNγ, interferon-γ; TNFα, tumor necrosis factor α; IL-2, interleukin-2.
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high VZV-IgG antibody level of almost 40,000 IU/ml was found, 
but medical records did not mention herpes zoster or symptoms 
suggesting this diagnosis. The high antibody level suggests that 
this patient is likely to have had a (subclinical) VZV reactivation 
that escaped diagnosis.
DiscUssiOn
Confirming our hypothesis, a reduced cellular immunity to VZV 
in GCA patients was demonstrated using IFNγ ELISpot, even 
when compared to an already at-risk age-matched HC group. 
Results in patients with PMR were found to be similar compared 
to age-matched controls. VZV-specific IgG levels were found to 
be similar when comparing the patient groups to the HC group.
It is widely accepted that cell-mediated immunity is an impor-
tant measure of susceptibility to VZV (24–26). Since HCs and 
GCA patients were shown to have similar total numbers of CD3+ 
T  lymphocytes, which probably are the main IFNγ producing 
cells among PBMCs (27), we can conclude that our results reflect 
a decreased cell-mediated immunity to VZV. Accordingly, GCA 
patients are even more prone to herpes zoster than the already 
at-risk healthy elderly population.
To date only one, for an epidemiological study relatively small, 
retrospective study investigated the incidence of herpes zoster 
in GCA patients (with 21 and 38 cases of herpes zoster in 204 
GCA patients and 407 controls, respectively). In this study, GCA 
patients did not seem to be at higher risk of herpes zoster than 
age-matched controls. However, with an incidence of over 11 per 
1,000 person years, the herpes zoster risk in GCA patients was 
found to be high (28). Interestingly, several large studies reported 
an increased risk of herpes zoster in persons (mostly diagnosed 
with rheumatoid arthritis) receiving glucocorticoid therapy 
(9–14). In our hospital, GCA patients usually start on 40–60 mg 
of prednisolone daily, while PMR patients start at a lower dose 
of 15–20  mg prednisolone daily. In both patient groups, the 
prednisolone dose is slowly tapered.
Because of the high risk, herpes zoster vaccination needs to 
be considered in this GCA patients. Ideally, vaccination would 
be administered at time of diagnosis, before patients reach a high 
cumulative dose of glucocorticoids. Herpes zoster vaccination 
has been shown to be safe in subjects receiving glucocorticoids, 
although most subjects studied received relatively low doses 
(18). Efficacy of herpes zoster vaccination in glucocorticoid 
treated patients is a topic that needs to be studied further, as only 
6Rondaan et al. Immunity to VZV in GCA and PMR
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humoral immune responses were evaluated in these patients 
previously (18).
Due to the limited number of patients included, no firm epide-
miologic conclusions can be drawn on the incidence of clinically 
overt herpes zoster in GCA or PMR patients in the present report. 
Furthermore, herpes zoster could have been missed before diag-
nosis and during follow-up, as it does not necessarily come to 
attention of the treating rheumatology specialist, especially dur-
ing more stable disease periods in which outpatient clinic visits 
are less frequent. As mentioned, for one patient notes on a herpes 
zoster period shortly before GCA disease onset were found in 
the medical records. In hindsight, another patient possibly had a 
VZV reactivation at time of GCA diagnosis.
No difference was found in the percentages of cytokine-pro-
ducing CD4+ and CD8+ T cells in response to VZV stimulation 
between GCA patients and controls. When evaluating low-level 
cell-mediated immune responses, ELISpot is considered to be 
more sensitive than intracellular flow cytometric analysis while 
cytokine flow cytometry allows for phenotypic discrimination of 
responding cells (25, 27). The effector function of T cells upon 
VZV-specific activation is more clearly seen during active secre-
tion of the cytokines, while flow cytometry shows the potential 
to react to VZV.
Polymyalgia rheumatica patients were shown to have a 
higher percentage of IL-2 and IFNγ producing CD4+ T  cells 
in response to VZV stimulation using flow cytometry. As the 
lymphocyte count in PMR patients was lower than in the HC 
group, the difference in absolute numbers of CD4+ T cells pro-
ducing cytokines in response to stimulation with VZV between 
these groups is probably less pronounced than suggested by the 
relative values.
Of note, as it is known that VZV-specific IgG levels only 
slowly decline after herpes zoster (29–31), the finding of similar 
VZV-specific IgG levels in patients at time of diagnosis and HCs, 
indicates that herpes zoster did not occur substantially more often 
in GCA and PMR patients in the months before onset of disease.
In recent years, several studies have investigated the link 
between VZV and GCA with the finding of VZV antigen in tem-
poral artery biopsies of a majority of GCA patients as the pivotal 
evidence claiming an etiologic role for VZV in GCA (32–34). 
Other research groups, however, did not detect VZV antigen 
nor VZV-DNA in temporal arteries of GCA patients (35–37). A 
recent paper by Rhee et al., describing a large retrospective study 
using an electronic database, reported an only modest association 
between antecedent infections and the incidence of GCA. GCA 
patients were more likely to have had a prior herpes zoster infec-
tion (median time from zoster to GCA of 6 years) than control 
subjects, but also had significantly more other infections, e.g., 
respiratory and urinary tract infections. No higher occurrence 
of clinically overt herpes zoster infections at time of diagnosis 
was found (38). Our results, demonstrating similar humoral 
immunity in GCA and PMR patients when compared to HCs, 
are in line with these results.
To the best of our knowledge, this is the first prospective study 
investigating both humoral and cellular immunity to VZV in GCA 
and PMR patients. Concluding with our most important result, 
a decreased cell-mediated immunity to VZV indicates an even 
higher risk to herpes zoster in GCA patients on glucocorticoid 
FigUre 4 | Levels of IgG antibodies against varicella zoster virus (VZV) among 35 giant cell arteritis (GCA) patients and 26 polymyalgia rheumatica (PMR) patients at 
different time points of follow-up, and 58 healthy control (HC) subjects. Bars show the median. T = 0 = before start of treatment with prednisolone; ≤2 months, 
within 2 months after start of treatment; 6 months, at approximately 6 months of follow-up; 1 year, at approximately 1 year of follow-up; ≥2 year, at approximately 
2 years of follow-up, or more.
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